Prognostic correlation between MTA2 expression level and colorectal cancer.
OBJECTIVE
Association of MTA2 expression with presence, development, metastasis and prognosis of colorectal cancer (CRC) was investigated.


METHODS
90 CRC-related cases with follow-up information were made into tissue microarrays according to the paired principle of cancer tissues and the adjacent tissues. Subsequently, the expression of MAT2 was detected with immunohistochemical analysis and SPSS software was finally utilized to analyze the relationships between experimental data and clinical indicatives.


RESULTS
Expression of MTA2 in CRC tissues were notably higher than their adjacent tissues (P < 0.001) and showed significant positive correlation with tumor grade (r(2) > 0, P < 0.01). Moreover, survival analysis indicated that MTA2 expression in cancer tissues, serving as an independent correlation factor, was significantly correlated with poor prognosis (P = 0.004).


CONCLUSIONS
MTA2 is a crucial biomarker that is closely related with prognosis of CRC and also a potential molecular target for evaluating the prognosis and treatment of CRC.
Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University Suzhou 215004, China ; Department of Radiotherapy and Oncology, The Affiliated Taizhou Hospital of Wenzhou Medical University Taizhou 317000, China.
Weijun
W
Ding
Department of Radiotherapy and Oncology, The Affiliated Taizhou Hospital of Wenzhou Medical University Taizhou 317000, China.
Wei
W
Hu
Department of Radiotherapy and Oncology, The Affiliated Taizhou Hospital of Wenzhou Medical University Taizhou 317000, China.
Haihua
H
Yang
Department of Radiotherapy and Oncology, The Affiliated Taizhou Hospital of Wenzhou Medical University Taizhou 317000, China.
Ting
T
Ying
Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University Suzhou 215004, China.
Ye
Y
Tian
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005260:Female; D006655:Histone Deacetylases / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012097:Repressor Proteins / Q000032:analysis*; D012307:Risk Factors; D013997:Time Factors; D046888:Tissue Array Analysis; D016896:Treatment Outcome; D015854:Up-Regulation
D014408:Biomarkers, Tumor; D012097:Repressor Proteins; C120917:MTA2 protein, human; D006655:Histone Deacetylases
CRC; MAT2; biomarker; immunohistochemistry; prognosis; tissue microarray